Scientists test if new drug can penetrate the Brain's defenses
NCT ID NCT05804227
Summary
This early-phase study aims to find out if the experimental drug ulixertinib can cross the blood-brain barrier and reach recurrent brain tumors called gliomas. It will enroll about 40 adults and teenagers (12+) whose tumors have a specific genetic change (MAPK-activated). The main goal is to measure how much of the drug gets into the tumor tissue during a short treatment window before planned surgery, or to see if it shows any anti-tumor activity in patients not having surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMAS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.